MedTrace Logo

Efficacy of Median Nerve Hydrodissection by Hyalase Versus Midazolam in the Treatment of Carpal Tunnel Syndrome:

NCT05344495 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-06-15

No results posted yet for this study

Summary

Comparing efficacy of hyalase and midazolam in median nerve entrapement neuropathy

Conditions

  • Pain, Neuropathic

Interventions

DRUG

hyalase group

bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.

DRUG

midazolam group

2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%

Sponsors & Collaborators

  • Minia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2022-07-20
Completion
2022-08-01

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05344495 on ClinicalTrials.gov